1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
644496182BBB3192F85256C7C007B9C51
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharmaceutical-diagnostic-companies-best-practices-in-partnerships-strategic-alliances?opendocument
18
19opendocument
2018.97.14.91
21
22
23
24/bestp/domrep.nsf
25DB




» Products & Services » » Business Operations » Alliances and Partnerships

Pharmaceutical & Diagnostic Companies: Best Practices in Partnerships & Strategic Alliances

DB Image

ID: 4362


Features:

Graphics


Words: 3,600


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
This 11-page document discusses the factors that contribute to a healthy and thriving partnership or alliance between pharmaceutical and diagnostic companies. A set of factors are described from the perspectives of both sides; however other factors, such as establishing the relationship early in drug development, are applicable to both.

Industries Profiled:
Pharmaceutical; Diagnostic; Research; Manufacturing; Biotech; Consumer Products; Medical Device


Companies Profiled:
Eli Lilly; bioMerieux; Visible Genetics; LipoScience; LabCorp; Tibotec-Virco; Cholestech; Diagnology; Bayer; Focus Technologies; Abbott Laboratories; AstraZeneca; GlaxoSmithKline; Becton Dickinson; Roche

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.